A protein that keeps metastatic breast cancer cells dormant
The time needed for breast cancer metastases (secondary lesions caused by cells that have escaped from the original tumour) to develop varies between patients, and little is known about the mechanisms that govern latency (the dormant state of cells that have already spread through the body). A study headed by ICREA researcher Roger Gomis at the Institute for Research in biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light on the molecular basis underlying how the expression of certain genes facilitates the spread of metastatic lesions.
Nuclei of metastatic breast cancer cells showing the protein MSK1 in green.
Cristina Figueras-Puig, IRB Barcelona
The team has studied the most common kind of breast tumour--estrogen-positive (ER +) and accounting for 80% of breast cancer tumour cases--that is characterised by a long period of latency with no symptoms.
MSK1, the protein that keeps tumour cells dormant
The team has identified the protein kinase MSK1 as a key regulator of dormant or latent metastases. Using clinical samples from patients, the scientists have confirmed that ER + breast cancer tumours that do not express MSK1 are associated with a risk of earlier relapse, while those that express this molecule will form metastases later.
"We are interested in understanding the mechanisms underlying metastasis and the time component of this process. Until now, little was known in preclinical models about the mechanisms that allow breast cancer cells to leave the latent state and even less is known in patients," explains Roger Gomis, head of the Growth Control and Cancer Metastasis Lab.
The researchers believe that in the future this discovery may benefit patients in two ways. Firstly, it will help to identify those with an imminent risk of relapse and to adjust the treatment for this prognosis. Secondly, attempts could be made to design a treatment to mimic the function of MSK1 kinase, with the aim to maintain metastatic lesions in a latent and asymptomatic state for as long as possible.
Original publication
Sylwia Gawrzak et al.; "MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer"; Nature Cell Biology; 2018
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Ariadne Expands Presence in South-East Asia - Genomax Technologies to Distribute Ariadne Software in the Region
A potent weapon against lymphomas - Mice with leukemia were cured
Combining therapies appears safe, may benefit patients with advanced liver cancer, UF scientists say
Biocatalysts are a bridge to greener, more powerful chemistry
FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients
First synthetic tissue model developed in which blood vessels can grow
Medicago's Pandemic Flu Vaccine Provides 100% Protection in Mice at Low Doses
Turning waste into microbial gold for a sustainable future - Zymofix secures €2 million to scale microbial solutions for sustainable agriculture and beyond
Alternative antimicrobial compounds could come from wastewater
Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian
Sinonasal cancer: AI facilitates breakthrough in diagnostics - Researchers have developed a method for classifying difficult-to-diagnose nasal cavity tumors
